Targeting both domestic and foreign markets, pharmaceutical companies are actively deploying antidepressant drugs

 As the problem of depression becomes more serious and attention is increasing, the antidepressant market ushered in growth
.
According to relevant statistics, in 2019, the sales of terminal antidepressant drugs in public medical institutions in China increased by 10% year-on-year, exceeding 9 billion yuan
.
In addition, data shows that the domestic antidepressant market will exceed 10 billion yuan in 2020 and is expected to reach 18.
4 billion yuan in 2022
.
In recent years, the domestic antidepressant market has been growing every year, and domestic pharmaceutical companies have made frequent moves in the field of antidepressant generic drugs
.
For example, in terms of product reviews, at present, more than a dozen antidepressant drugs in China have been reviewed
.
Recently, some corporate antidepressant drugs have been reviewed
.
That is, the 4 generic vothiaxetine hydrobromide tablets submitted by Kanghong Pharmaceutical were successfully approved for marketing recently, and they are deemed to have passed the consistency evaluation
.
The original research of vothiaxetine hydrobromide tablets was jointly developed by Danish Lundbeck and Takeda.
It also has 5-HT transporter (SERT) inhibitory effect and 5-HT1A receptor activation Its effects and 5-HT3 receptor antagonism were approved to officially enter China in 2017 for the treatment of depression in adults
.
It is reported that there are currently 14 domestic acceptance numbers for vothiaxetine hydrobromide tablets, involving Yiling Wanzhou, Yangzijiang Pharmaceutical, Jiangsu Haosen Pharmaceutical, CSPC Ouyi Pharmaceutical, Chengdu Kanghong Pharmaceutical, and Zhengda Tianqing, Chengdu Better Pharmaceutical and other companies
.
According to relevant statistics, in 2020, in the national hospital sales market, vothiaxetine hydrobromide tablets will achieve sales of more than 70 million yuan, and in 2021, H1 will exceed 60 million
.
According to the industry, antidepressants have huge market potential.
At the same time, with the implementation of medical policies such as consistency evaluation, mass procurement, and medical insurance negotiations, domestic pharmaceutical companies have begun to deploy in the field of antidepressants
.
According to statistics, there are currently 4 new antidepressant drugs developed and approved by domestic pharmaceutical companies.
They are Fosun Pharma's modified new drug "Reboxetine mesylate" and Xinyi Barretta's modified new drug "Moclobemide", Shengda Chemical Pharmaceutical's innovative drug "Lurasidone", and Luye Pharma's improved new drug "Quetiapine Fumarate"
.
With the launch of various drugs, domestic depression patients are also ushered in new treatment options
.
It is understood that in addition to actively deploying the domestic market, domestic pharmaceutical companies are also actively expanding into overseas markets
.
For example, Yiling Pharmaceutical issued an announcement on November 10, stating that the generic paroxetine tablets declared by the wholly-owned subsidiary Yiling Wanzhou International Pharmaceutical Co.
, Ltd.
to the U.
S.
Food and Drug Administration (FDA) have been approved
.
Paroxetine tablets are selective central nervous system serotonin reuptake inhibitors, which can increase the concentration of serotonin in the synaptic cleft, exert an antidepressant effect, and have a weaker effect on other transmitters.
The impact is small
.
Paroxetine tablets are indicated for depression, and can also treat obsessive-compulsive disorder, panic disorder or social anxiety disorder
.
According to Yiling Pharmaceuticals, this time paroxetine tablets have been approved by the US FDA, which indicates that Yiling Wanzhou International Pharmaceutical Co.
, Ltd.
has the qualification to sell the product in the US market and will have a positive impact on the company's expansion in the US market.

.
For example, Luye Pharmaceutical has also stated that LY03005, whose marketing application has been accepted by CDE, has entered the new drug marketing application stage in the United States, and completed phase I clinical trials in Japan
.
The company plans to register and market the product in the United States, China, Japan, Europe and other countries and regions
.